Cardiotoxic complications of antitumor therapy in cancer patients: ways of prevention

• Dariya D. Perepechko
• Alexey A. Korolev
• Galina S. Mal’
• Elena B. Artyushkova
• Mikhail P. Gladchenko

Abstract

Cardiotoxic complications, which arise during the treatment of oncological diseases, are one of the most common problems of cardiology today. The main manifestations of this pathology are ischemic heart disease, arterial hypertension, various rhythm disturbances, thromboembolism. In many cases, these complications, but not the underlying disease, become the mortality causes. A wide variety of cardiotoxic effects indicates the need for timely prevention and careful monitoring of the patient before treatment, during therapy and even after its completion. This article discusses the possible manifestations of cardiotoxic adverse events in patients receiving chemotherapy, possible ways of their prevention and prevention.

Keywords:cardiotoxicity; cardioncology; antitumor drugs; prevention of cardiotoxicity

References

1. Vasyuk Yu.A., Shkol’nik E.L., Nesvetov V.V., Shkol’nik L.D., Varlan G.V., Pil’shchikov A.V. Anthracycline cardiotoxicity: prospects for the use of ivabradine. Kardiosomatika [Cardiosomatics]. 2012; 3 (4): 65–9. (in Russian)

2. Gumerova K.S., Sakhautdinova G.M., Polyakova I.M. Cardiovascular toxicity induced by the use of antitumor drugs and modern methods of treatment of tumor neoplasms. Kreativnaya khirurgiya i onkologiya [Creative Surgery and Oncology]. 2019; (9): 285–92. (in Russian)

3. Ibragimova A.A., Emelina E.I., Gendlin G.E., Nikitin I.G. Possibilities of prevention and treatment of lesions of the cardiovascular system caused by the use of antitumor drugs. Rossiyskiy meditsinskiy zhurnal [Russian Medical Journal]. 2018; (24): 316–23. (in Russian)

4. Kalyuta T. Yu., Kiselev A.R., Bazarbayeva A.H. Cardiotoxicity of drugs: possibilities of prevention and correction. Saratovskiy nauchno-meditsinskiy zhurnal [Saratov Journal of Medical Scientific Research]. 2020; (16): 736–43. (in Russian)

5. Meshcherina N.S., Mikhaylenko T.S., Khardikova E.M., Saraev I.A., Leont’eva T.S. Cardiovascular toxicity induced by chemotherapy and targeted drugs: mechanisms of development, approaches to diagnosis and prevention. Chelovek i ego zdorov’e [Human and His Health]. 2021; 24 (4): 24–33. DOI: https://doi.org/10.21626/vestnik/2021-4/04 (in Russian)

6. Plokhova E.V. Cardioncology. Basic principles of prevention and treatment of cardiotoxicity on the background of chemotherapy in cancer patients. Klinicheskaya praktika [Clinical Practice]. 2019; 10 (1): 32–42. (in Russian)

7. Khlyamov S.V., Mal’ G.S., Artyushkova E.B., Gladchenko M.P. Chemotherapy of oncological diseases and the risk of developing a cardiotoxic profile on the example of a human recombined monoclonal antibody bevahizumab. Innova. 2023; 9 (1): 52–9. (in Russian)

8. Advani P.P., Ballman K.V., Dockter T.J., Colon-Otero G., Perez E.A. Long-term cardiac safety analysis of NCCTG N 9831 (alliance) adjuvant trastuzumab trial. J Clin Oncol. 2016; 34 (6): 581–7. DOI: https://doi.org/10.1200/JCO.2015.61.8413

9. Almeida L.B., Pecanha T., Mira P.A.C., et al. Cardiac autonomic dysfunction in offspring of hypertensive parents during exercise. Int J Sports Med. 2017; 38 (14): 1105–10. DOI: https://doi.org/10.1055/s-0043-119883

10. Armenian S.H., Sun C.L., Shannon T., et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood. 2011; 118 (23): 6023–9.

11. Baldini E., Prochilo T., Salvadori B., et al. Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety. Br J Cancer. 2004; 91 (1): 45–9. DOI: https://doi.org/10.1038/sj.bjc.6601883

12. Burstein H., Kuter I., Campos S., et al. Clinical activity of trastuzumab and vinorelbine in women with HER 2-overexpressing metastatic breast cancer. J Clin Oncol. 2001; 19: 2722–30.

13. Cappetta D., Urbanek K., Rossi F., De Angelis A. Anthracycline cardiotoxicity: new actors on the stage. Transl Cancer Res. 2018; 7 (suppl 5): S 580–83.

14. Chen M.H., Colan S.D., Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res. 2011; 108 (5): 619–28. DOI: https://doi.org/10.1161/CIRCRESAHA.110.224519

15. Chen J.Y., Lee Y.L., Tsai W.C., et al. Cardiac autonomic functions derived from short-term heart rate variability recordings associated with heart rate recovery after treadmill exercise test in young individuals. Heart Vessels. 2011; 26 (3): 282–8. DOI: https://doi.org/10.1007/s00380-010-0048-6

16. Chow E.J., Baker K.S., Lee S.J., et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol. 2014; 32 (3): 191–8. DOI: https://doi.org/10.1200/JCO.2013.52.6582

17. Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. Target Oncol. 2011; 6 (4): 189–95. DOI: https://doi.org/10.1007/s11523-011-0203-8

18. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015; 12 (11): 620. DOI: https://doi.org/10.1038/nrcardio.2015.133

19. Fumoleau P., Roché H., Kerbrat P., et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol. 2006; 17 (1): 85–92. DOI: https://doi.org/10.1093/annonc/mdj034

20. Moazeni S., Cadeiras M., Yang E.H., Deng M.C., Nguyen K.-L. Anthracycline induced cardiotoxicity: biomarkers and «Omics» technology in the era of patient specific care. Clin Transl Med. 2017; 6 (1): 1–12.

21. Pinder M.C., Duan Z., Goodwin J.S., Hortobagyi G.N., Giordano S.H. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007; 25 (25): 3808–15. DOI: https://doi.org/10.1200/JCO.2006.10.4976

22. Piccart-Gebhart M., Holmes E., Baselga J., De Azambuja E., Dueck A.C., Viale G., et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol. 2016; 34: 1034–42.

23. Romond E.H., Jeong J.H., Rastogi P., et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012; 30 (31): 3792–9. DOI: https://doi.org/10.1200/JCO.2011.40.0010

24. Ryberg M., Nielsen D., Cortese G., Nielsen G., Skovsgaard T., Andersen P.K. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008; 100 (15): 1058–67. DOI: https://doi.org/10.1093/jnci/djn206

25. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97 (11): 2869–79.

26. Tamargo J., Caballero R., Delpón E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 2015; 38: 129–52.

27. Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37 (36): 2768–801. DOI: https://doi.org/10.1093/eurheartj/ehw211

28. Zeglinski M., Ludke A., Jassal D., et al. Trastuzumab-induced cardiac dysfunction: a «dual-hit». Exp Clin Cardiol. 2011; 16: 70–4.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)